[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335133-105":59,"doc-detail-335133-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","survival-prediction-in-patients-with-gynecological-cancer-irradiated-for-brain-metastases","Survival prediction in patients with gynecological cancer irradiated for brain metastases","","Background and purpose: This large population-based, retrospective, single-center study examined prognostic factors in patients with brain metastases originating from gynecological cancers. Material and methods: One hundred and forty-four patients treated with radiotherapy were identified, and variables including primary cancer type, age, performance status, number of brain metastases, extracranial disease, and treatment modality were analyzed. Kaplan–Meier overall survival estimation and Cox proportional hazards regression were used to build a prognostic index. Results: Median overall survival was 6.2 months; 40% died within 3 months after radiotherapy. The developed index stratified patients into good, intermediate, and poor risk groups with median survival of 13.5, 4.0, and 2.4 months, respectively.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/survival-prediction-in-patients-with-gynecological-cancer-irradiated-for-brain-metastases/335133/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/survival-prediction-in-patients-with-gynecological-cancer-irradiated-for-brain-metastases/335133.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main goal regarding gynecological cancer brain metastases?","Question",{"text":112,"@type":113},"The study aimed to identify prognostic factors in patients with brain metastases originating from gynecological cancers and to develop a scoring tool to support patient selection by risk.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which factors were assessed to predict overall survival?",{"text":117,"@type":113},"Primary cancer diagnosis, age, performance status, number of brain metastases, presence of extracranial disease, and the type of brain metastasis treatment were evaluated.",{"name":119,"@type":110,"acceptedAnswer":120},"How did overall survival vary across the risk groups from the prognostic index?",{"text":121,"@type":113},"The prognostic index separated patients into three risk groups with median overall survival of 13.5 months (good), 4.0 months (intermediate), and 2.4 months (poor).",{"name":123,"@type":110,"acceptedAnswer":124},"What interpretation did the authors draw about radiotherapy and outcomes?",{"text":125,"@type":113},"Patients with brain metastases from gynecological cancers had a poor prognosis overall, and those in the high-risk group showed particularly poor outcomes; the authors suggest that omission of radiotherapy could be considered for these patients.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},335133,1790466971,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":4},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","ACTA ONCOLOGICA 2024, VOL. 63, 206–212  \n[https://doi.org/10.2340/1651-226X.2023.34899](https://doi.org/10.2340/1651-226X.2023.34899)  \nORIGINAL ARTICLE  \nSurvival prediction in patients with gynecological cancer irradiated for brain metastases  \nSilje Skjelsvik Osa,c,f, Kjersti Skiparc,d, Eva Skovlunde, Ivar Homplanda, Taran Paulsen Hellebustf, Marianne Grønlie Gurena,c, Kristina Lindemannb,c and Esten Søndrol Nakkena  \na Department of Oncology, Oslo University Hospital, Oslo, Norway; bDepartment of Gynecological Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; c Institute of Clinical Medicine, University of Oslo, Oslo, Norway; dDepartment of Oncology, Telemark Hospital Trust, Skien, Norway; e Department of Public Health and Nursing, Norwegian University of Science and Technology (NTNU), Trondheim, Norway; fDepartment of Medical Physics, Oslo University Hospital, Oslo, Norway  \nABSTRACT  \nBackground and purpose: This large population-based, retrospective, single-center study aimed to identify prognostic factors in patients with brain metastases (BM) from gynecological cancers.  \nMaterial and methods: One hundred and forty four patients with BM from gynecological cancer treated with radiotherapy (RT) were identified. Primary cancer diagnosis, age, performance status, number of BM, presence of extracranial disease, and type of BM treatment were assessed. Overall survival (OS) was calculated using the Kaplan–Meier method and the Cox proportional hazards regression model was used for multivariable analysis. A prognostic index (PI) was developed based on scores from independent predictors of OS.  \nResults: Median OS for the entire study population was 6.2 months. Forty per cent of patients died within 3 months after start of RT. Primary cancer with the origin in cervix or vulva (p = 0.001), Eastern Cooperative Oncology Group (ECOG) 3–4 (p \u003C 0.001), and the presence of extracranial disease (p = 0.001) were associated with significantly shorter OS. The developed PI based on these factors, categorized patients into three risk groups with a median OS of 13.5, 4.0, and 2.4 months for the good, intermediate, and poor prognosis group, respectively.  \nInterpretation: Patients with BM from gynecological cancers carry a poor prognosis. We identified prognostic factors and developed a scoring tool to select patients with better or worse prognosis. Patients in the high-risk group have a particular poor prognosis, and omission of RT could be considered.  \nARTICLE HISTORY  \nReceived 13 December 2023  \nAccepted 8 March 2024 Published 21 April 2024  \nKEYWORDS  \nRadiotherapy; brain metastases; ovarian cancer; endometrial  \ncancer; cervical cancer; vulvar cancer; palliation  \nIntroduction  \nThe incidence of brain metastases (BM) from solid cancers has increased over the recent decades [1]. Reasons for this development may include more frequent and better imaging techniques, prolonged survival due to improved systemic therapy regimens, and greater awareness among clinicians and patients [2] . Still, the occurrence of BM is a rare event, in particular in patients with gynecological cancers, with reported incidences rates of 0.3– 0.9% in cervical cancer, 0.4–1.2% in endometrial cancer, 0.3–2.2% in ovarian cancer, and 0–0 . 7% in vulvar cancer [2–5] .  \nThe standard management of BM includes best supportive care (BSC) including steroids, surgical excision, and radiotherapy (RT) . RT is administered as whole brain radiotherapy (WBRT), stereotactic radiotherapy (SRT), or partial brain radiotherapy (PBRT), solitary or in combination. Randomized controlled trials comparing WBRT with SRT for treatment of BM in solid cancers, have not found differences in overall survival (OS) [6, 7]. However, the well-known risk of developing cognitive deficit after WBRT [8], as well as the longer treatment time for delivering WBRT,  \nincreasing the patient burden, supports the use of SRT when feasible.  \nThere are no current guidelines for tre","cbCaidUK516wdTzN","https://ap.wps.com/l/cbCaidUK516wdTzN","pdf",1752359,"English","# Abstract\n## Background and purpose\n## Material and methods\n## Results\n## Interpretation\n# Introduction\n## Incidence and rationale\n## Standard management approaches\n## Guideline landscape","[{\"question\":\"What was the study’s main goal regarding gynecological cancer brain metastases?\",\"answer\":\"The study aimed to identify prognostic factors in patients with brain metastases originating from gynecological cancers and to develop a scoring tool to support patient selection by risk.\"},{\"question\":\"Which factors were assessed to predict overall survival?\",\"answer\":\"Primary cancer diagnosis, age, performance status, number of brain metastases, presence of extracranial disease, and the type of brain metastasis treatment were evaluated.\"},{\"question\":\"How did overall survival vary across the risk groups from the prognostic index?\",\"answer\":\"The prognostic index separated patients into three risk groups with median overall survival of 13.5 months (good), 4.0 months (intermediate), and 2.4 months (poor).\"},{\"question\":\"What interpretation did the authors draw about radiotherapy and outcomes?\",\"answer\":\"Patients with brain metastases from gynecological cancers had a poor prognosis overall, and those in the high-risk group showed particularly poor outcomes; the authors suggest that omission of radiotherapy could be considered for these patients.\"}]","Survival prediction in patients with gynecological cancer irradiated for brain metastases | PDF",1790009763,18]